Company intelligence / Profile preview
Ovid Therapeutics
New York City, New York, United Statespmc.ncbi.nlm.nih.gov ↗
- Ownership
- Public · OVID
- Employees
- ~23
- Development stage
- Phase 1
01
Overview
Ovid Therapeutics has advanced several novel small molecule candidates into early clinical development targeting neurological diseases with high unmet need. OV329, a next-generation GABA aminotransferase inhibitor for treatment-resistant seizures, completed Phase 1 with topline data expected in mid-to-late 2025. OV350, the first KCC2 direct activator from their library, entered Phase 1 in Q1 2025 for psychosis associated with NSD/LBD. The oral KCC2 activator OV4071 will enter human studies in Q2 2026. The ROCK2 inhibitor program OV888/GV101 completed a successful Phase 1 trial and was set to begin a proof-of-concept study in CCM but this was paused pending further review after competitor results; additional neurovascular applications are being explored.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Graviton Bioscience Corporation – collaboration on ROCK2 inhibitors including OV888/GV101 for CCM and other neurovascular conditions.
04
Financials
- Market cap
- $513.3M
- Total revenue
- $733K
- Enterprise value
- $408.8M
Beyond the preview
Go deeper on Ovid Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ovid Therapeutics.